NHS England drops routine prescribing of cross-sex hormones to minors
After the Cass Review, the British national health service is drawing further consequences: cross-sex hormones for young people under 18 are removed from the standard package. The justification is hard.
What NHS England is doing
- Stop on routine prescribing of cross-sex hormones to minors.
- Suspension of new prescriptions until the policy is finalised.
- Mandatory re-evaluation and monitoring of existing patients.
- Shift from an affirmative model to an evidence-based model.
This step follows NHS England's earlier decision to remove puberty blockers from standard care. The reasoning behind both decisions is identical: there is no quality evidence that these interventions are safe and effective in the long term in people under 18.
The justification
"The evidence on safety, risks, benefits and outcomes of prescribing cross-sex hormones to people under 18 was very limited." — NHS England
"There is insufficient evidence for the safety and clinical effectiveness of these hormones." — NHS England
These are not statements by a lobby group. These are formulations by the British national health service that has been carrying out the policy itself for years. The Cass Review has knocked the scientific foundation out from under affirmative gender care and NHS England is now drawing the consequences step by step.
What this means for the wider debate
The international movement of British, Swedish, Finnish and American revisions all point the same way. The affirmative model that is still the norm in the Netherlands is being systematically dismantled elsewhere. Not on the basis of political preference, but on the basis of systematic reviews which show that the evidence base is insufficient for permanent medical interventions in minors.
What this means for the Netherlands
The Amsterdam protocol served for decades as international standard. That same protocol is now being dismantled again in the countries that adopted it. Dutch gender clinics have so far made no comparable revision. As a result, the Netherlands is slowly standing alone in a Western context that is rediscovering caution.
Conclusion
The NHS England revision is not a temporary policy choice. It is an institutional acknowledgement that cross-sex hormones in minors do not meet the evidence threshold that applies to every other medical intervention. Whoever continues to offer these procedures is no longer delivering care but conducting an experiment.